Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical advice. Research peptides discussed are not FDA-approved for human use. Always consult a licensed healthcare professional. See our full disclaimer.
Quick Answer: Cagrisema is an investigational weight-loss therapy combining cagrilintide (a long-acting amylin analog) with semaglutide (a GLP-1 receptor agonist). The fixed-dose weekly injection targets both satiety pathways simultaneously, producing greater weight loss than semaglutide alone. In Phase 3 REDEFINE trials reported in late 2024–2025, cagrisema produced roughly 20% weight loss at 68 weeks, better than semaglutide (~15%) but slightly below tirzepatide-class dual agonists (~22%). Cagrisema's main advantage is durability of effect and lower GI side-effect burden in some patients. As of early 2026 it is expected to receive regulatory approval within 12 months. Dosing, safety, and positioning continue to evolve; it is not yet commercially available.
What Is Cagrisema?
Cagrisema is a combination therapy that places two distinct peptides — cagrilintide and semaglutide — into a single weekly subcutaneous injection. Cagrilintide is a long-acting analog of amylin, a pancreatic peptide co-secreted with insulin that regulates satiety, gastric emptying, and glucagon suppression. Semaglutide is the well-known GLP-1 receptor agonist that underpins Ozempic and Wegovy.
The rationale is mechanistic synergy: amylin and GLP-1 act on partially overlapping but distinct satiety pathways, and combining them produces greater weight loss than either alone. Novo Nordisk began developing cagrisema as a next-generation anti-obesity therapy to extend its GLP-1 franchise beyond semaglutide monotherapy.
How Cagrisema Works
Cagrilintide (Amylin Analog)
Amylin reduces food intake through multiple mechanisms: slowing gastric emptying, suppressing glucagon secretion, and activating satiety receptors in the hindbrain. Endogenous amylin has a half-life of only 12 minutes; cagrilintide is engineered for once-weekly dosing through lipidation similar to semaglutide.
Semaglutide (GLP-1 Agonist)
GLP-1 receptor agonists reduce appetite through central nervous system pathways (primarily hypothalamic POMC neurons and hindbrain centers), slow gastric emptying, and improve insulin sensitivity. Semaglutide has become the foundational anti-obesity drug of the late 2020s.
Complementary Action
Amylin and GLP-1 pathways converge on satiety but activate partially different neuronal populations. Combining both amplifies the appetite-suppressing signal, often resulting in more complete satisfaction at smaller meals and more durable long-term adherence.
Clinical Trial Results
The REDEFINE program (REDEFINE 1, REDEFINE 2, and REDEFINE 3) has provided the primary Phase 3 evidence for cagrisema in obesity.
- REDEFINE 1: Weight loss of approximately 20.4% at 68 weeks with cagrisema 2.4 mg cagrilintide + 2.4 mg semaglutide vs 15.0% for semaglutide alone and 2.3% for placebo.
- REDEFINE 2: In obesity with type 2 diabetes, weight loss of 13.7% at 68 weeks with cagrisema, comparable HbA1c reduction to semaglutide.
- REDEFINE 3: Cardiovascular outcomes trial, ongoing at start of 2026.
Results were highly statistically significant. Approximately 40% of patients in REDEFINE 1 achieved ≥25% weight loss, which is clinically transformative.
The ~20% weight loss represents a step forward from semaglutide monotherapy but sits below tirzepatide's ~22.5% in SURMOUNT trials. Head-to-head comparisons are ongoing.
Dosing and Administration
The standard cagrisema dosing ramp is similar to other GLP-1 agents, with incremental escalation to minimize GI side effects. Based on current trial data (subject to change on approval):
| Week | Cagrilintide (mg) | Semaglutide (mg) | Frequency |
|---|---|---|---|
| 1–4 | 0.25 | 0.25 | Weekly SC |
| 5–8 | 0.5 | 0.5 | Weekly SC |
| 9–12 | 1.0 | 1.0 | Weekly SC |
| 13–16 | 1.7 | 1.7 | Weekly SC |
| 17+ | 2.4 | 2.4 | Weekly SC |
Maintenance dose is 2.4 mg cagrilintide + 2.4 mg semaglutide weekly. Titration can be paused if GI symptoms become problematic.
Side Effects and Tolerability
Cagrisema's side-effect profile mirrors GLP-1 agonists with added amylin-related effects.
- GI effects: Nausea, vomiting, diarrhea, constipation — most common and dose-dependent
- Gallbladder issues: Cholecystitis and gallstone risk similar to semaglutide
- Hypoglycemia: Rare in non-diabetic users; more concerning with concurrent insulin/sulfonylureas
- Injection site reactions: Mild redness, itching
- Pancreatitis risk: Small elevated risk, as with all GLP-1 class
- Fatigue: Early adaptation phase
Notably, in some trials, cagrisema produced somewhat lower nausea rates than semaglutide monotherapy at equivalent anti-obesity effect, possibly because amylin's satiety contribution allows lower effective GLP-1 dosing.
Cagrisema vs Alternatives
| Compound | Weight Loss (68 wk) | Mechanism | FDA Status (April 2026) |
|---|---|---|---|
| Semaglutide (Wegovy) | ~15% | GLP-1 | Approved |
| Tirzepatide (Zepbound) | ~22.5% | GIP + GLP-1 | Approved |
| Cagrisema | ~20.4% | Amylin + GLP-1 | Pending approval |
| Retatrutide | ~24% | GIP + GLP-1 + glucagon | Phase 3 |
| Orforglipron | ~15% | Oral GLP-1 | Pending approval |
| Survodutide | ~19% | Glucagon + GLP-1 | Phase 3 |
The weight-loss race in 2026 has produced a crowded field. Cagrisema's positioning is strong for patients who need significant weight loss without tirzepatide-level GI burden or those unable to tolerate GIP agonism.
Access and Cost
As of early 2026, cagrisema is in the final stages of FDA and EMA review, with approval expected within 12 months. Once approved, pricing is likely to match or slightly exceed Wegovy ($1,000–1,400 monthly in the US without insurance). Coverage will initially be limited and subject to typical anti-obesity prescription hurdles.
Compounded versions may become available, though cagrilintide is not currently on the FDA shortage list that has enabled compounded semaglutide and tirzepatide.
Patient Considerations
- Severe obesity (BMI ≥40): Strong candidate once approved, especially if semaglutide has plateaued.
- Obesity with type 2 diabetes: Reasonable alternative to tirzepatide.
- GI-sensitive patients: May tolerate cagrisema better than tirzepatide in some cases.
- Weight-loss maintenance: Evidence for long-term durability is still emerging.
- Pregnancy planning: Should be discontinued 8+ weeks before attempting pregnancy (class effect).
Bottom Line
Cagrisema represents the next practical step beyond semaglutide monotherapy for obesity management — significantly more weight loss through a well-designed dual mechanism without the side-effect burden of more aggressive compounds. It doesn't claim the weight-loss crown (that belongs to tirzepatide and retatrutide at the 22–25% range) but fills an important niche for patients who need more than semaglutide and less than GIP-agonist GI burden. Once approved, it will be a meaningful addition to the anti-obesity toolkit, particularly for Novo Nordisk's existing GLP-1 franchise.
Recommended Research Vendors
For researchers sourcing compounds discussed in this article, the following vendors maintain third-party purity testing, transparent sourcing, and established reputations in the research peptide community. WolveStack earns a small commission on referred purchases, which funds our research and writing work — this does not affect our editorial evaluation of each vendor.
🧪 Ascension Research
Third-party tested research peptides. Transparent COAs, reliable sourcing, and fast shipping make Ascension a top choice for researchers.
Visit Ascension →🧬 Particle Peptides
Pharma-grade purity with full HPLC/MS certificates for every batch. Particle is known for clinical-grade quality and precision research protocols.
Visit Particle →💎 Limitless Life
Popular for novel and hard-to-source research compounds. Limitless offers a broad catalog of frontier peptides backed by third-party testing.
Visit Limitless →Frequently Asked Questions
No. Cagrisema combines semaglutide with cagrilintide (an amylin analog) into a single weekly injection. Semaglutide alone is just the GLP-1 agonist. The combination produces greater weight loss than semaglutide monotherapy.
Not in terms of peak weight loss. Tirzepatide produces ~22.5% weight loss at 68 weeks vs ~20% for cagrisema. However, cagrisema may produce fewer GI side effects in some patients and offers an alternative mechanism that some respond to better. Individual response varies.
As of April 2026, FDA and EMA review is in final stages. Approval is widely expected within 12 months. Timelines depend on regulatory action and could shift based on additional data requests.
Initial insurance coverage for cagrisema is likely to follow typical anti-obesity drug patterns: limited coverage with prior authorization requirements, significant copays, and patient hurdles. Employer-sponsored GLP-1 coverage programs may extend to cagrisema over time.
Cagrilintide is a long-acting analog of endogenous amylin with a half-life of ~7 days (vs 12 minutes for natural amylin). This is achieved through lipidation similar to semaglutide's modification. Cagrilintide also has slightly modified pharmacodynamics optimized for sustained satiety.
Yes, once approved. Cagrisema is likely to be a natural next step for patients who have plateaued on semaglutide, particularly those who tolerated semaglutide well but need additional weight loss.
Nausea, vomiting, diarrhea, and constipation are most common — typical of GLP-1 class. Gallbladder problems, pancreatitis, and hypoglycemia (in diabetics) are rarer but notable. Titration schedules minimize GI symptoms.
Cagrilintide is not currently on the FDA shortage list, so legal compounding is limited. Some research vendors sell cagrilintide for laboratory research, but this is not approved for human use and purity/dose varies widely.
You Might Also Like
About the Author
The WolveStack research team compiles peer-reviewed scientific literature, clinical trial data, and accumulated biohacking community experience to deliver evidence-first peptide education. Our guides reflect the current state of research and common practices in the researcher community, with emphasis on critical evaluation and transparent discussion of what is and isn't known.